Cargando…
The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
We have previously demonstrated that platelet-poor plasma (PPP) obtained from patients with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is characterized by a hypercoagulable state and contains hyperactivated platelets and considerable numbers of already-formed amyloid fibrin(ogen) or fibrinalo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413879/ https://www.ncbi.nlm.nih.gov/pubmed/36015078 http://dx.doi.org/10.3390/ph15080931 |
_version_ | 1784775859269271552 |
---|---|
author | Nunes, Jean M. Kruger, Arneaux Proal, Amy Kell, Douglas B. Pretorius, Etheresia |
author_facet | Nunes, Jean M. Kruger, Arneaux Proal, Amy Kell, Douglas B. Pretorius, Etheresia |
author_sort | Nunes, Jean M. |
collection | PubMed |
description | We have previously demonstrated that platelet-poor plasma (PPP) obtained from patients with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is characterized by a hypercoagulable state and contains hyperactivated platelets and considerable numbers of already-formed amyloid fibrin(ogen) or fibrinaloid microclots. Due to the substantial overlap in symptoms and etiology between Long COVID/PASC and ME/CFS, we investigated whether coagulopathies reflected in Long COVID/PASC—hypercoagulability, platelet hyperactivation, and fibrinaloid microclot formation—were present in individuals with ME/CFS and gender- and age-matched healthy controls. ME/CFS samples showed significant hypercoagulability as judged by thromboelastography of both whole blood and platelet-poor plasma. The area of plasma images containing fibrinaloid microclots was commonly more than 10-fold greater in untreated PPP from individuals with ME/CFS than in that of healthy controls. A similar difference was found when the plasma samples were treated with thrombin. Using fluorescently labelled PAC-1, which recognizes glycoprotein IIb/IIIa, and CD62P, which binds P-selectin, we observed hyperactivation of platelets in ME/CFS hematocrit samples. Using a quantitative scoring system, the ME/CFS platelets were found to have a mean spreading score of 2.72 ± 1.24 vs. 1.00 (activation with pseudopodia formation) for healthy controls. We conclude that ME/CFS is accompanied by substantial and measurable changes in coagulability, platelet hyperactivation, and fibrinaloid microclot formation. However, the fibrinaloid microclot load was not as great as was previously noted in Long COVID/PASC. Fibrinaloid microclots, in particular, may contribute to many ME/CFS symptoms, such as fatigue, seen in patients with ME/CFS, via the (temporary) blockage of microcapillaries and hence ischemia. Furthermore, fibrinaloid microclots might damage the endothelium. The discovery of these biomarkers represents an important development in ME/CFS research. It also points to possible uses for treatment strategies using known drugs and/or nutraceuticals that target systemic vascular pathology and endothelial inflammation. |
format | Online Article Text |
id | pubmed-9413879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94138792022-08-27 The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Nunes, Jean M. Kruger, Arneaux Proal, Amy Kell, Douglas B. Pretorius, Etheresia Pharmaceuticals (Basel) Article We have previously demonstrated that platelet-poor plasma (PPP) obtained from patients with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is characterized by a hypercoagulable state and contains hyperactivated platelets and considerable numbers of already-formed amyloid fibrin(ogen) or fibrinaloid microclots. Due to the substantial overlap in symptoms and etiology between Long COVID/PASC and ME/CFS, we investigated whether coagulopathies reflected in Long COVID/PASC—hypercoagulability, platelet hyperactivation, and fibrinaloid microclot formation—were present in individuals with ME/CFS and gender- and age-matched healthy controls. ME/CFS samples showed significant hypercoagulability as judged by thromboelastography of both whole blood and platelet-poor plasma. The area of plasma images containing fibrinaloid microclots was commonly more than 10-fold greater in untreated PPP from individuals with ME/CFS than in that of healthy controls. A similar difference was found when the plasma samples were treated with thrombin. Using fluorescently labelled PAC-1, which recognizes glycoprotein IIb/IIIa, and CD62P, which binds P-selectin, we observed hyperactivation of platelets in ME/CFS hematocrit samples. Using a quantitative scoring system, the ME/CFS platelets were found to have a mean spreading score of 2.72 ± 1.24 vs. 1.00 (activation with pseudopodia formation) for healthy controls. We conclude that ME/CFS is accompanied by substantial and measurable changes in coagulability, platelet hyperactivation, and fibrinaloid microclot formation. However, the fibrinaloid microclot load was not as great as was previously noted in Long COVID/PASC. Fibrinaloid microclots, in particular, may contribute to many ME/CFS symptoms, such as fatigue, seen in patients with ME/CFS, via the (temporary) blockage of microcapillaries and hence ischemia. Furthermore, fibrinaloid microclots might damage the endothelium. The discovery of these biomarkers represents an important development in ME/CFS research. It also points to possible uses for treatment strategies using known drugs and/or nutraceuticals that target systemic vascular pathology and endothelial inflammation. MDPI 2022-07-27 /pmc/articles/PMC9413879/ /pubmed/36015078 http://dx.doi.org/10.3390/ph15080931 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nunes, Jean M. Kruger, Arneaux Proal, Amy Kell, Douglas B. Pretorius, Etheresia The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
title | The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
title_full | The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
title_fullStr | The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
title_full_unstemmed | The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
title_short | The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) |
title_sort | occurrence of hyperactivated platelets and fibrinaloid microclots in myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413879/ https://www.ncbi.nlm.nih.gov/pubmed/36015078 http://dx.doi.org/10.3390/ph15080931 |
work_keys_str_mv | AT nunesjeanm theoccurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT krugerarneaux theoccurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT proalamy theoccurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT kelldouglasb theoccurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT pretoriusetheresia theoccurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT nunesjeanm occurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT krugerarneaux occurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT proalamy occurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT kelldouglasb occurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs AT pretoriusetheresia occurrenceofhyperactivatedplateletsandfibrinaloidmicroclotsinmyalgicencephalomyelitischronicfatiguesyndromemecfs |